News - Page 7
NB win Phase I of CRACK IT Challenge 29: ImmuLiver – securing £99,711 funding
Newcells Biotech are one…
Read update
WHO WE ARE
A passionate, rigorous and dedicated team of scientists who deliver the highest quality services and products. Your reliable and knowledgeable partner.
Read updateWHAT WE DO
Learning from structures in the body, we recreate functional 3D in vitro models through innovation and science. Our models incorporate the “best biology” and are predictive of new drugs’…
Read updateHOW WE DO IT
Using our expertise in induced pluripotent stem cells (iPSCs), cellular physiology and organoid technology, we build functional pre-clinical in vitro models of kidney, retina, liver and lung. We engineer…
Read updateWHY WE DO IT
Our purpose is to bridge the gap between scientific discovery and patients. We make a difference by providing better predictions of clinical outcomes.
Read update
Looking forward: A year in review
2018 has been a significant year for Newcells Biotech. We have secured substantial investment, launched new, ground-breaking products, attended global events and expanded our every growing team. Here are some of…
Read update
Newcells head to Boston
International Trade Mission
Read update
ESTIV 2018 International Congress
Congress Round-Up The International Congress on In Vitro Toxicology (ESTIV2018) organised by the European Society of Toxicology was held in Berlin this October 2018. This year marks its 20th meeting, with the general theme of new…
Read update
iPSC-derived retinal organoids
The start of the field of stem cell biology dates back to 1938, when Hans Spemann suggested that a differentiated nucleus can express pluripotency. This was followed by decades…
Read update
Leading drug transport & drug toxicity expert, Dr Colin Brown joins NB
Newcells Biotech has announced that Dr Colin Brown, one of the world’s leading experts on drug transport and drug toxicity in kidney will join the company as Director of ADMET Technology….
Read update
22nd North American ISSX Meeting – Montréal, Canada (15th-19th July)
The meeting brings together individuals who are working on drug/xenobiotic research across a diverse range of fields such as clinical pharmacology and therapeutics, toxicology, oncology, endocrinology, physiology, biochemistry, medicinal…
Read update
NB secures £2M investment from NVM Private Equity & Northstar Ventures to accelerate hiPSC growth
Founded on the technology of Prof Lyle Armstrong and Prof Majlinda Lako from Newcastle University, the company is at the forefront of the production and differentiation of human induced…
Read update
